Business Context and Reporting Period
Company: DiaMedica Therapeutics Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 25, 2024
Event: Entry into a Material Definitive Agreement for a Private Placement of equity securities.
Key Financial Metrics
This filing reports a capital raise event rather than periodic financial performance. Key metrics include:
- Shares Issued: 4,720,000 common shares.
- Purchase Price: $2.50 per share.
- Gross Proceeds: Approximately $11.8 million (before fees and expenses).
- Expected Closing Date: On or about June 28, 2024.
Note: The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures.
Material Changes
The primary material change is the execution of Securities Purchase Agreements with accredited investors. This transaction represents a significant increase in the company's capital base pending closing. No prior comparable period financial data is provided in this specific filing to calculate percentage changes in operational metrics.
Guidance, Outlook, and Use of Proceeds
Use of Proceeds: The Company intends to use net proceeds to:
- Expand clinical trials into preeclampsia (a life-threatening, pregnancy-associated vascular disorder).
- Fund other working capital and general corporate purposes.
Registration Rights: The Company agreed to file a Resale Registration Statement within 10 business days of closing and use commercially reasonable best efforts to have it declared effective within 30 calendar days (or 75 days in the event of a full SEC review). Failure to meet these deadlines may result in liquidated damages.
Investor Verification Checklist
- Verify the actual closing date and final net proceeds after deducting offering expenses.
- Confirm the filing and effectiveness status of the Resale Registration Statement.
- Review the specific clinical trial milestones for preeclampsia to be funded by this capital.
- Check for any subsequent filings regarding the dilution impact of the 4,720,000 new shares.